HBIO — Harvard Bioscience Income Statement
0.000.00%
Last trade - 00:00
- $167.17m
- $199.45m
- $112.25m
- 68
- 60
- 26
- 50
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 116 | 102 | 119 | 113 | 112 |
Cost of Revenue | |||||
Gross Profit | 64.5 | 58 | 67.7 | 62.3 | 66.4 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 116 | 104 | 117 | 120 | 110 |
Operating Profit | 0.377 | -1.66 | 2.07 | -6.93 | 1.89 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.5 | -7.29 | -0.14 | -9.18 | -2.56 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.69 | -7.81 | -0.288 | -9.52 | -3.42 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -4.69 | -7.81 | -0.288 | -9.52 | -3.42 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.69 | -7.81 | -0.288 | -9.52 | -3.42 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.083 | -0.136 | 0.013 | -0.196 | -0.075 |